Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy

Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy

Multidrug resistance protein 2 (MRP2), encoded by the ATP-binding cassette C2 (ABCC2) gene, is an efflux pump located on the apical membrane of many polarized cells, which transports conjugate compounds by an ATP-dependent mechanism. The correlation of G1249A ABCC2 polymorphism with the development...

Full description

Bibliographic Details
Main Authors:	Mirakhorli, Mojgan, Abdul Rahman, Sabariah, Abdullah, Syahrilnizam, Vakili, Masoud, Rozafzon, Reza, Khoshzaban, Ahad
Format:	Article
Language:	English
Published:	Spandidos Publications 2013
Online Access:	http://psasir.upm.edu.my/id/eprint/29782/1/Multidrug%20resistance%20protein%202%20genetic%20polymorphism%20and%20colorectal%20cancer%20recurrence%20in%20patients%20receiving%20adjuvant%20FOLFOX.docx

Similar Items

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
by: Kazuaki Harada, et al.
Published: (2019-03-01)

Dynamic impact of inﬂammation-based indices in colorectal cancer patients receiving FOLFOX-based chemotherapy
by: Tao Y, et al.
Published: (2019-04-01)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
by: Yun-Ting Lou, et al.
Published: (2014-01-01)

Clinical Significance of MMP7 Levels in Colorectal Cancer Patients Receiving FOLFOX4 Chemotherapy Treatment
by: Zhou Y, et al.
Published: (2023-06-01)

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
by: I-Ping Yang, et al.
Published: (2019-08-01)

Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy
by: Gui-Nan Lin, et al.
Published: (2016-01-01)

Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4
by: Mehdi Dehghani, et al.
Published: (2015-07-01)

Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
by: Bertrand Le Roy, et al.
Published: (2016-01-01)

Combination of neoadjuvant and adjuvant chemotherapy with FOLFOX compared with adjuvant chemotherapy in management of locally advanced rectal cancers: a randomized trial of a promising therapeutic approach
by: Mandana Biniaz, et al.
Published: (2024-07-01)

olymorphism and Expression of Drug resistance Genes in Colorectal Cancer Patients Given Adjuvant Folfox-4 Chemotheraphy
by: Mirakhrli, Mogjan
Published: (2011)

Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
by: Chikako Funasaka, et al.
Published: (2019-08-01)

Influence of TYMP Polymorphism on Clinical Outcomes of Colorectal Cancer Patients Received Adjuvant Chemotherapy After R0 Resection
by: ZHANG Yu, et al.
Published: (2018-07-01)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
by: Huang Che-Jen, et al.
Published: (2008-11-01)

Retrospective Analysis of the Safety of FOLFOX Compared to CAPOX for Adjuvant Treatment of Stage III Colorectal Cancer in Newfoundland Patients
by: Joshua N. McShane, et al.
Published: (2022-09-01)

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy
by: Luiz Carlos Porcello Marrone, et al.
Published: (2013-01-01)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
by: Huabin Hu, et al.
Published: (2020-12-01)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
by: Jii Bum Lee, et al.
Published: (2020-04-01)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
by: Bożena Cybulska-Stopa, et al.
Published: (2020-03-01)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
by: Portales Fabienne, et al.
Published: (2009-09-01)

Adjuvant chemotherapy for colorectal cancer.
by: Kerr, D, et al.
Published: (1996)

Adjuvant chemotherapy for stage II colorectal cancer: who should receive therapy and with what?
by: Midgley, R, et al.
Published: (2005)

FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms
by: Wei Lu, et al.
Published: (2020-02-01)

Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients
by: Takeda Hiroshi, et al.
Published: (2009-08-01)

Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
by: Wai Cheong Soon, et al.
Published: (2014-09-01)

Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
by: Shunji Okada, et al.
Published: (2017-08-01)

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
by: Hye Eun Park, et al.
Published: (2021-07-01)

Effects on Cardiac Biomarkers in Colorectal Cancer Patients Treated With FOLFOX
by: Nusrat Bano, et al.
Published: (2024-05-01)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
by: Abdosaleh Jafari, et al.
Published: (2023-05-01)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
by: Keisuke Okuno, et al.
Published: (2023-01-01)

KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
by: Yanhong Deng, et al.
Published: (2015-08-01)

FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis
by: Yiyi Zhang, et al.
Published: (2020-03-01)

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)

Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II
by: Matej Horvat, et al.
Published: (2016-01-01)

Leucovorin-induced Hypersensitivity Reaction in a Patient with Metastatic Colorectal Cancer Treated with Cetuximab Plus FOLFOX Chemotherapy: A Case Report
by: Minna Kim, et al.
Published: (2023-12-01)

Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy
by: Julia Sánchez-Gundín, et al.
Published: (2019-03-01)

Global impact of KRAS mutations patterns in FOLFOX treated metastatic colorectal cancer
by: David eMolinas Zocche, et al.
Published: (2015-03-01)

Precision medicine for adjuvant chemotherapy of resected colorectal cancer
by: Yuji Miyamoto, et al.
Published: (2020-11-01)

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
by: Diana Groza, et al.
Published: (2018-05-01)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
by: Ren Hui, et al.
Published: (2011-09-01)

Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
by: Jia X, et al.
Published: (2023-03-01)